Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E versus OVCON 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E versus OVCON 50.
ENOVID-E vs OVCON-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation, and alters cervical mucus and endometrial lining.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
One tablet (norethindrone 1 mg and ethinyl estradiol 50 mcg) orally once daily for 21 days followed by 7 days of placebo or no tablets.
None Documented
None Documented
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Norethindrone: 5-14 hours (terminal); ethinyl estradiol: 7-20 hours. Clinical context: Steady-state reached within 5-7 days; half-life allows once-daily dosing with stable contraceptive efficacy.
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Renal: 40-60% (metabolites, primarily glucuronide conjugates; <1% unchanged). Fecal: 30-50% (via biliary elimination).
Category C
Category C
Oral Contraceptive
Oral Contraceptive